CA9 and glioblastoma: McIntyre and colleagues provided proof of principle data for this co-targeting strategy by showing that genetic depletion of CAIX in combination with bevacizumab in models of colorectal cancer and glioblastoma resulted in a significant delay in tumor growth (McIntyre et al., 2012).